Abstract:e16509 Background: At present, bladder cancer is diagnosed mainly through cystoscopy as the "gold standard" method, which is invasive, costly, and painful for patients. Meanwhile, the current non-invasive liquid biopsy approaches, such as FISH or cytology, still do not show adequate performance in the diagnosis of bladder cancer because of the unsatisfactory sensitivity. Therefore, developing a novel method that performs higher sensitivity and specificity, especially negative predictive value(NPV) is an urgent issue to be addressed and will be very helpful for the clinical application. Methods: From October 2019 to October 2020, we designed a multicenter, prospective study, in which 321 hematuria patients were enrolled, including 218 males and 103 females, and their average age was 56. Based on the final pathological diagnosis, 121 patients were confirmed as bladder cancer and 200 samples were benign urinary diseases. 100ml urine samples were collected from each patient before the endoscopy examination. The Genetron Uro-18 assay, which included a 17 gene mutation panel and the methylation test on ONECUT2, was used in this study. The regions in the panel were selected based on the TCGA database, as well as previous publications. 321 urine DNA libraries were generated using multiplex PCR methods and then sequenced on the Ion S5 System. The CpG-sites on the ONECUT2 gene were detected by bisulfite-specific real-time PCR. Results: In these samples, a total of 205 oncogenic mutations were found in 13 genes in the panel. Mutations on TERT, PIK3CA, FGFR3, and TP53 genes showed significantly higher occurrence. 103 samples were found to be mutation-positive, 92 of which were pathologically confirmed as bladder cancers. When only gene mutations were considered, the sensitivity and specificity of this assay were 76.0% and 94.5%, respectively. The methylation of ONECUT2 had a performance in the test with a sensitivity of 74.4% and specificity of 93.0%. Combining the mutation panel with the ONECUT2 methylation test will improve the sensitivity (86.0%) of this assay, but slightly hampered the specificity (91.0%). The positive predictive value(PPV) and negative predictive value(NPV) of the combination were 85.2% and 91.5%. The sensitivity was as high as 91.5% when low-grade bladder cancer samples were excluded. In contrast, the sensitivity of cytology and FISH tests were only 48.4% and 62.0%. Conclusions: The novel urine-based liquid biopsy assay has excellent performances in the diagnosis of bladder cancer, with sensitivity and NPV reaching 86.0% and 91.5%, which improved significantly than cytology and FISH tests. Thus this assay will be more beneficial for patients with urinary diseases which significantly reduces the current burden of repeat cystoscopies and cytology tests.

Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer

Comparison of DNA methylation and cytology tests in urine to detect upper tract urothelial carcinoma: A paired-design diagnostic study

Diagnostic and Prognostic Role of BTA, NMP22, Survivin and Cytology in Urothelial Carcinoma.

An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese.

[Clinical Value of Combined Detection with Urinary Bladder Cancer Antigen, Hyaluronic Acid and Cytokeratin 20 in Diagnosis of Bladder Cancer].

Superior Molecular Pathology of Urothelial Bladder Cancer Using Urinary Cell-Free DNA.

The clinical validity of urinary pellet DNA monitoring for the diagnosis of recurrent bladder cancer

Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments

Detection of Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Bladder Carcinoma, and Urothelial Carcinoma with Gross Hematuria Using Selected Urine-Dna Methylation Biomarkers: A Prospective, Single-Center Study

An Accurate Diagnostic Approach for Urothelial Carcinomas Based on Novel Dual Methylated DNA Markers in Small-Volume Urine

Detection of Urothelial Bladder Carcinoma via Microfluidic Immunoassay and Single-Cell DNA Copy-Number Alteration Analysis of Captured Urinary-Exfoliated Tumor Cells

Combined use of urinary Survivin detection and liquid-based cytology for the early diagnosis of bladder urothelial carcinoma.

Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer.

Diagnostic accuracy of DnA cytometry and urinary cytology in urothelial carcinomas

Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology

Abstract 4878: Enhancing non-invasive detection of urothelial carcinoma through combined cytology and methylation profiling of urinary cell-free DNA

Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer

A multicenter, prospective evaluation of a urine-based assay for bladder cancer diagnosis.

UCseek: Ultrasensitive Early Detection and Recurrence Monitoring of Urothelial Carcinoma by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Sediment DNA

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

The value of combined detection of BLCA-1 and BLCA-4 in urine for early diagnosis and surveillance for bladder cancer